Certain Shares of Swedish Orphan Biovitrum AB (publ) are subject to a Lock-Up Agreement Ending on 14-MAR-2024. These Shares will be under lockup for 182 days starting from 14-SEP-2023 to 14-MAR-2024.

Details:
The Company has, in a customary manner, undertaken not to, without the prior written consent of BofA Securities Europe SA and Danske Bank, from today and for a period of 180 calendar days from the announcement of the final outcome of the rights issue, carry out a capital increase, issue of shares or similar action, dispose of shares or certain share-related instruments or take any other similar action that would have the effect of transferring economic rights attached to the shares.

In addition, Investor AB (publ) has, under the subscription undertaking, undertaken not to, without the prior written consent of the Company, reduce its holdings in the Company until the record date for the rights issue, or dispose of any subscription rights received under the rights issue during the period from the record date for the rights issue until and included the last day of the subscription period. Investor AB (publ) shall, however, not be restricted from divesting shares pursuant to previously issued call options.